antibody/PNE-based biologic agent ABBV-461

A biologic agent composed of an antibody fragment targeting an as of yet unidentified tumor-associated antigen (TAA) that is linked to a 14 aa peptide epitope, or alpha-peptide neo-epitope (PNE), recognizable by autologous alpha-PNE switchable CAR-T cells CLBR001, that may be used to activate CLBR001. Upon administration of the antibody-based biologic agent ABBV-461, and upon co-administration of CLBR001, the antibody moiety targets and binds to tumor cells expressing the TAA. In turn, the PNE part of ABBV-461 binds to the binding domain of CLBR001, thereby activating CLBR001. This induces selective toxicity in and causes lysis of the TAA-expressing tumor cells to which ABBV-461 is bound.